Targeted Therapies in Cancer Treatment: Unveiling the Latest Breakthroughs and Promising Approaches

Vishal Rai[1], Yash Gupta[2], Shobhit Prakash Srivastava[3], Amrita Shukla[4], Nisha Bano[5] and Soban Khan[6]

[1,2,3,4,5,6]Department of Pharmacy, Dr. M.C. Saxena College of Pharmacy, Uttar Pradesh, INDIA.

[1]Corresponding Author: viahalrai2016@gmail.com

www.jrasb.com || Vol. 2 No. 6 (2023): December Issue

ABSTRACT

This review article delves into the realm of cancer treatment, specifically focusing on targeted therapies. It aims to present the most recent breakthroughs and promising approaches in this rapidly evolving field. Targeted therapies have emerged as a revolutionary approach in cancer treatment, aiming to selectively and precisely attack cancer cells while sparing normal tissues. This article explores various targeted therapy strategies, including monoclonal antibodies, small molecule inhibitors, immunotherapies, and gene therapies. In recent years, there have been significant advancements in understanding the molecular and genetic basis of cancer, which has led to the identification of novel therapeutic targets. The article sheds light on these newly discovered targets and highlights their potential in designing more effective and personalized treatment regimens for cancer patients. Furthermore, the review addresses the challenges and limitations associated with targeted therapies, such as resistance mechanisms and the heterogeneity of tumors. Strategies to overcome these obstacles are discussed, including combination therapies and the development of next-generation targeted agents. The role of precision medicine in cancer treatment is also explored, emphasizing the importance of biomarker-guided therapy selection to optimize treatment outcomes. Additionally, the review touches upon the integration of targeted therapies with conventional treatments, such as chemotherapy and radiation therapy, to enhance overall treatment efficacy. Finally, the article examines ongoing clinical trials and preclinical studies that are investigating cutting-edge targeted therapies, showcasing the potential impact of these approaches in transforming cancer care.

In conclusion, targeted therapies in cancer treatment represent a rapidly expanding field with remarkable breakthroughs and promising avenues. Understanding the latest advancements and challenges in this domain is essential to harness the full potential of targeted therapies and ultimately improve patient outcomes in the battle against cancer.

Keywords- Cancer prevention, Anticancer.

I. INTRODUCTION

Cancer remains a formidable health challenge, affecting millions of lives worldwide. Over the years, considerable progress has been made in the realm of cancer treatment, leading to improved outcomes. However, conventional therapies like chemotherapy and radiation have limitations in terms of efficacy and potential side effects. In recent times, targeted therapies have emerged as a promising frontier in cancer treatment, revolutionizing the way we approach the disease.[1]

Overview of Targeted Therapies in Cancer Treatment:

Targeted therapies represent a novel approach to cancer treatment, focusing on specific molecular targets present on cancer cells. Unlike traditional treatments, which indiscriminately attack rapidly dividing cells, targeted therapies are designed to home in on unique features of cancer cells. This precision allows for a more effective attack on cancer while minimizing damage to healthy cells, reducing adverse effects for patients.

These therapies work by interfering with specific molecules or pathways that play crucial roles in cancer cell growth and survival. By doing so, targeted therapies aim to halt or slow down the progression of cancer, potentially leading to better treatment outcomes. Furthermore, targeted therapies can be tailored to the genetic makeup of an individual's tumor, making them an essential component of precision medicine.[2]

Importance of Targeted Approaches in Precision Medicine:

Precision medicine is a patient-centered approach that takes into account individual genetic and molecular characteristics when devising treatment plans. Targeted therapies are at the forefront of precision medicine, as they offer personalized treatments based on the unique attributes of each patient's cancer.

Through advanced genomic analysis and molecular profiling, oncologists can identify specific genetic alterations driving tumor growth. Armed with this knowledge, they can select targeted therapies that are most likely to be effective against the identified molecular targets. This individualized approach enhances treatment response rates while minimizing the risk of adverse reactions.[3]

Moreover, precision medicine allows oncologists to predict a patient's response to treatment more accurately. This knowledge is invaluable in optimizing treatment strategies, avoiding unnecessary treatments, and improving overall patient outcomes.[4]

Targeted therapies have ushered in a new era of cancer treatment, providing hope for more effective and less toxic interventions. The integration of targeted approaches into precision medicine has elevated patient care by tailoring treatments to individual genetic profiles. As research and technology continue to advance, targeted therapies hold the potential to transform cancer treatment and significantly improve patient outcomes. The future of cancer care lies in the continued exploration and utilization of these groundbreaking therapies in the fight against this complex disease.[4]

II. MOLECULAR BASIS OF TARGETED THERAPIES

Targeted therapies in cancer treatment rely on a deep understanding of the molecular basis of cancer. These therapies are designed to specifically target key genetic and molecular alterations that drive cancer cell growth and survival. By focusing on the unique characteristics of cancer cells, targeted therapies aim to disrupt their signaling pathways, leading to more effective and less toxic treatments.[5]

Key Genetic and Molecular Alterations in Cancer:

Numerous genetic and molecular alterations have been identified in different types of cancer. These alterations can promote uncontrolled cell growth, evade cell death, and enable cancer cells to spread throughout the body. Some of the key alterations include:

1. Oncogene activation: Oncogenes are genes that, when mutated or overexpressed, promote cell proliferation and survival. Examples include HER2 in breast cancer and EGFR in lung cancer.

2. Tumor suppressor gene inactivation: Tumor suppressor genes normally regulate cell growth and prevent tumor formation. Mutations in these genes can lead to uncontrolled cell growth. Examples include TP53 (p53) in various cancers and BRCA1/2 in breast and ovarian cancer.

3. Dysregulated cell signaling pathways: Abnormalities in critical signaling pathways, such as the MAPK and PI3K pathways, can contribute to cancer development and progression.[6]

Gene	Alteration	Cancer Type
TP53	Mutation	Many types of cancer
RB1	Mutation	Retinoblastoma, breast cancer, and other types of cancer
EGFR	Mutation, amplification	Lung cancer, head and neck cancer, and other types of cancer
KRAS	Mutation	Lung cancer, colorectal cancer, and other types of cancer
BRAF	Mutation	Melanoma, thyroid cancer, and other types of cancer
RET	Fusion	Thyroid cancer, medullary thyroid cancer, and other types of cancer
ALK	Fusion	Lung cancer, anaplastic large cell lymphoma, and other types of cancer
NTRK1	Fusion	Sarcoma, breast cancer, and other types of cancer
NTRK3	Fusion	Sarcoma, breast cancer, and other types of cancer

Role of Biomarkers in Identifying Suitable Targets:

Biomarkers are measurable indicators that help identify specific molecular alterations in a patient's tumor. They play a vital role in guiding the selection of appropriate targeted therapies. Biomarker analysis involves techniques such as genomic sequencing, gene expression profiling, and protein analysis.[7]

Some commonly used biomarkers in targeted therapies include:

1. HER2/neu: Overexpression of HER2 in breast cancer patients is an indication for HER2-targeted therapies like trastuzumab.

2. ALK fusion: Detection of ALK gene rearrangement in non-small cell lung cancer (NSCLC) patients suggests eligibility for ALK inhibitors like crizotinib.

3. BRAF V600E: Presence of this mutation in melanoma patients makes them candidates for BRAF inhibitors like vemurafenib.[8]

Understanding the molecular basis of targeted therapies and the role of biomarkers in identifying

suitable treatment targets has opened up new avenues in precision medicine. As we delve deeper into cancer genomics, the potential to develop more effective and personalized therapies for cancer patients continues to expand.

III. TYPES OF TARGETED THERAPIES

1. Small Molecule Inhibitors:

Small molecule inhibitors are a class of targeted therapies that interfere with specific molecules involved in cancer cell growth and survival. These inhibitors are orally administered drugs that can penetrate cells and target intracellular signaling pathways. By binding to the targeted molecules, small molecule inhibitors disrupt the signaling cascades, thereby halting tumor growth and inducing cancer cell death. Examples of small molecule inhibitors include imatinib targeting BCR-ABL in chronic myeloid leukemia (CML) and vemurafenib targeting BRAF V600E in melanoma.[9]

2. Monoclonal Antibodies:

Monoclonal antibodies (mAbs) are engineered to recognize and bind to specific proteins present on the surface of cancer cells. These antibodies can mark cancer cells for destruction by the immune system or directly interfere with cell signaling. By leveraging the immune system's natural ability to target abnormal cells, mAbs can induce an immune response against cancer. Notable examples include trastuzumab, an mAb targeting HER2 in breast cancer, and rituximab targeting CD20 in B-cell lymphomas.[10]

3. Gene Therapies and Viral Vectors:

Gene therapies utilize genetically modified viruses or vectors to deliver therapeutic genes into cancer cells. The viral vectors can integrate into the cancer cell's DNA, altering its function and inhibiting tumor growth. Additionally, these therapies can be designed to induce apoptosis (programmed cell death) in cancer cells. CAR-T cell therapy is an example of gene therapy where patients' T-cells are genetically modified to express chimeric antigen receptors (CARs) targeting specific antigens on cancer cells, such as CD19 in B-cell leukemias and lymphomas.[11,13]

Type of Targeted Therapy	How it Works	Examples of Drugs
Type of Targeted Therapy	Attach to specific targets on the surface of cancer cells, blocking their growth or ability to spread.	Trastuzumab (Herceptin), cetuximab (Erbitux), rituximab (Rituxan)

Small-molecule inhibitors	Block the activity of specific proteins that are involved in cancer cell growth and survival.	Imatinib (Gleevec), sunitinib (Sutent), gefitinib (Iressa)
Antiangiogenesis inhibitors	Block the growth of new blood vessels that tumors need to grow and spread.	Bevacizumab (Avastin), sunitinib (Sutent), cediranib (Zactima)
Immunomodulatory drugs	Stimulate the immune system to attack cancer cells.	Ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo)

These different types of targeted therapies have significantly advanced cancer treatment, offering more precise and effective approaches for patients. Ongoing research and clinical trials continue to expand the repertoire of targeted therapies, raising hopes for further improvements in cancer management.[12]

IV. IMMUNE CHECKPOINT INHIBITORS

Understanding Immune Checkpoints and their Role in Cancer:

Immune checkpoints are regulatory molecules in the immune system that maintain self-tolerance and prevent excessive immune responses against healthy tissues. However, cancer cells can exploit these checkpoints to evade immune surveillance and escape destruction. Immune checkpoint inhibitors are a class of immunotherapies that target these inhibitory molecules, reactivating the immune response against cancer.[14]

One of the key immune checkpoints targeted by these inhibitors is the programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1. When PD-L1 on cancer cells binds to PD-1 on T cells, it inhibits T cell activity, allowing cancer cells to avoid detection and destruction. Immune checkpoint inhibitors block this interaction, enabling T cells to recognize and attack cancer cells effectively.[15]

Successes and Challenges in Immunotherapy:

The success of immune checkpoint inhibitors has been remarkable in several cancer types. In clinical trials, these therapies have shown durable responses and prolonged survival rates in patients with advanced cancers who had exhausted other treatment options. Notable successes include pembrolizumab and nivolumab, both PD-1 inhibitors, which have demonstrated significant efficacy in melanoma, lung cancer, and other malignancies.[16,17]

Despite these successes, challenges persist in immunotherapy. Not all patients respond to immune checkpoint inhibitors, and tumor microenvironments can be immunosuppressive, limiting the effectiveness of these therapies. Biomarkers like PD-L1 expression have been used to predict response to checkpoint inhibitors, but their reliability remains an area of active research. Additionally, immune-related adverse events, though generally manageable, can occur as the immune system is reactivated, necessitating close monitoring and management.[18]

The development of immune checkpoint inhibitors has brought a new dimension to cancer treatment, unleashing the potential of the immune system to fight cancer. While challenges remain, ongoing research and clinical efforts are dedicated to refining these therapies and expanding their applicability to benefit more patients with various cancer types.[18]

V. TARGETED THERAPIES FOR SPECIFIC CANCER TYPES

1. Breast Cancer:

In breast cancer, targeted therapies focus on specific molecular alterations that contribute to tumor growth. For example, human epidermal growth factor receptor 2 (HER2)-positive breast cancer can be treated with HER2-targeted therapies like trastuzumab, pertuzumab, and ado-trastuzumab emtansine. Hormone receptor-positive breast cancer can be treated with hormonal therapies that block estrogen or progesterone receptors, such as tamoxifen and aromatase inhibitors.[19]

2. Lung Cancer:

In lung cancer, targeted therapies are designed to inhibit specific genetic mutations that drive tumor growth. EGFR inhibitors like gefitinib and osimertinib are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations. ALK inhibitors, such as crizotinib and alectinib, are used for patients with ALK gene rearrangements. ROS1 and BRAF inhibitors are also emerging as targeted therapies for specific subsets of lung cancer patients.[20]

3. Colorectal Cancer:

In colorectal cancer, targeted therapies mainly focus on blocking the vascular endothelial growth factor (VEGF) pathway and the epidermal growth factor receptor (EGFR). Bevacizumab is an anti-VEGF antibody that inhibits blood vessel formation in the tumor. EGFR inhibitors like cetuximab and panitumumab target the EGFR pathway in KRAS wild-type colorectal cancer.[21]

4. Melanoma:

In melanoma, targeted therapies are directed towards the BRAF mutation, which is present in about half of all melanomas. BRAF inhibitors like vemurafenib and dabrafenib specifically target the mutated BRAF protein, inhibiting its activity. However, resistance can develop, so combination therapies with MEK inhibitors like trametinib have shown better efficacy.[22]

5. Leukemias and Lymphomas:

For leukemias and lymphomas, targeted therapies include monoclonal antibodies and kinase inhibitors. In chronic lymphocytic leukemia (CLL), the anti-CD20 antibody rituximab is used, while in B-cell

lymphomas, it is used in combination with chemotherapy. In chronic myeloid leukemia (CML), tyrosine kinase inhibitors like imatinib, nilotinib, and dasatinib target the BCR-ABL fusion gene.[23]

Targeted therapies for specific cancer types have transformed cancer treatment by honing in on precise molecular targets, leading to improved outcomes and reduced side effects for patients. As research continues, the potential for further advancements in targeted therapies is bright, offering hope for better treatments and increased survival rates.[23]

Cell receptors and targeted therapy

VI. EMERGING APPROACHES AND COMBINATIONS

1. Combination Therapies to Overcome Resistance:

Resistance to targeted therapies is a significant challenge in cancer treatment. To address this, researchers are exploring combination therapies that involve using two or more drugs with complementary mechanisms of action. These combinations aim to target multiple pathways involved in tumor growth, making it harder for cancer cells to develop resistance.[24]

For instance, in melanoma, combining BRAF and MEK inhibitors has shown promising results in overcoming acquired resistance to BRAF inhibitors alone. Additionally, immunotherapies like immune checkpoint inhibitors are being combined with targeted therapies to enhance the immune response against cancer cells while concurrently inhibiting specific molecular targets.[24]

2. Nanoparticle-based Drug Delivery Systems:

Nanoparticle-based drug delivery systems are a cutting-edge approach in cancer treatment. These systems involve encapsulating anticancer drugs within tiny nanoparticles that can target specific tissues or cancer cells. Nanoparticles can protect drugs from degradation and enhance their accumulation at the tumor site, improving treatment efficacy while minimizing systemic toxicity.[25]

Various types of nanoparticles, such as liposomes, polymeric nanoparticles, and gold nanoparticles, have been developed to deliver chemotherapeutic agents, targeted therapies, and even gene therapies. The ability to load multiple drugs into nanoparticles allows for combination therapies within a single delivery system, maximizing the therapeutic potential.[25]

Emerging approaches like combination therapies and nanoparticle-based drug delivery systems hold tremendous promise in improving cancer treatment outcomes. As research progresses, these novel strategies are expected to play an increasingly vital role in personalized and more effective cancer therapies.

Approach	Description
Immunotherapy	Stimulates the immune system to attack cancer cells.
Gene therapy	Delivers genes to cancer cells to either kill them or stop them from growing.
Nanomedicine	Uses nanoparticles to deliver drugs or other therapies to cancer cells.
Precision medicine	Uses information about a patient's individual cancer to tailor treatment to their specific needs.
Combination therapy	Uses two or more therapies together to treat cancer.

VII. CLINICAL TRIALS AND REGULATORY LANDSCAPE

1. Overview of Current Clinical Trials and their Outcomes:

Clinical trials are essential for evaluating the safety and efficacy of new cancer treatments before they can be approved for widespread use. These trials involve carefully designed studies in human subjects to assess the potential benefits and risks of investigational drugs or therapies.

In the context of cancer treatment, clinical trials often focus on targeted therapies, immunotherapies, and novel combinations of existing treatments. These trials aim to identify treatments that can improve patient outcomes, increase survival rates, and minimize adverse effects. The outcomes of clinical trials can vary, ranging from successful results that lead to FDA approval to inconclusive findings that may necessitate further investigation **[26].**

Phase	Description
Phase I	Tests safety and dosage of a new drug in a small group of people.
Phase II	Tests effectiveness of a new drug in a larger group of people.
Phase III	Compares a new drug to standard treatment in a large group of people.
Phase IV	Monitors the safety and effectiveness of a new drug after it has been approved for use.

2. FDA Approval Process and Future Directions:

The U.S. Food and Drug Administration (FDA) plays a crucial role in regulating the approval and use of new cancer treatments. The FDA approval process involves rigorous evaluation of data from preclinical studies and clinical trials to ensure the safety and efficacy of drugs before they are marketed to the public.

For cancer therapies, the FDA may grant accelerated approval for treatments that show significant benefits in early-phase trials. However, full approval may require further verification through larger, randomized trials. Additionally, the FDA continuously evaluates post-approval data to monitor the long-term safety and effectiveness of drugs.

Future directions in the regulatory landscape include the adoption of novel trial designs, such as basket trials and adaptive trials, to efficiently assess multiple treatments across different cancer types and patient populations. Moreover, efforts are underway to streamline the approval process for promising therapies, ensuring that innovative treatments reach patients in a timely manner.**[27]**

The continuous progress in clinical trials and the evolving regulatory landscape are vital for advancing cancer treatment options. By adhering to rigorous standards, improving trial design, and embracing innovation, researchers and regulatory agencies can enhance the efficiency and effectiveness of cancer clinical trials, ultimately benefiting patients and providing hope for improved cancer care in the future.

VIII. CHALLENGES AND LIMITATIONS IN CANCER TREATMENT

1. Drug Resistance and Tumor Heterogeneity:

Drug resistance is a significant challenge in cancer treatment that can lead to treatment failure and disease progression. Cancer cells can develop resistance to targeted therapies by acquiring new mutations or activating alternative pathways. This adaptability of cancer cells poses a major hurdle in achieving long-term control of the disease.

Tumor heterogeneity is another limitation in cancer treatment. Within a single tumor, there can be a diverse population of cancer cells with varying genetic and molecular characteristics. Some cells may be susceptible to treatment, while others are resistant, making it challenging to effectively target all cancer cells in a heterogeneous tumor.**[28]**

2. Side Effects and Toxicities:

Many cancer treatments, including chemotherapy and radiation therapy, can cause significant side effects and toxicities. While these treatments target rapidly dividing cancer cells, they can also affect healthy cells that divide quickly, such as hair follicles and cells lining the digestive tract. This leads to adverse effects like hair loss, nausea, and fatigue, reducing the patient's quality of life.

Immunotherapies and targeted therapies also come with their own set of side effects, as they activate the immune system or target specific molecular pathways. Immune-related adverse events, such as skin rashes and autoimmune reactions, can occur with immunotherapies, requiring careful monitoring and management.**[29]**

Addressing these challenges and limitations is crucial to improving cancer treatment outcomes. Ongoing research and advances in precision medicine and immunotherapy hold promise in overcoming drug resistance and tumor heterogeneity. Additionally, efforts to develop therapies with better target specificity and reduced side effects are essential in enhancing patient care and minimizing treatment-related toxicities.

IX. FUTURE PERSPECTIVES IN CANCER TREATMENT

1. Personalized Medicine and Targeted Therapies:

The future of cancer treatment lies in personalized medicine and targeted therapies. With advancements in genomics and molecular profiling, oncologists can identify specific genetic alterations and molecular characteristics of each patient's tumor. This information allows for the selection of the most appropriate targeted therapies tailored to the individual's unique cancer profile.

Personalized medicine aims to optimize treatment outcomes by matching the right drug to the right patient. By focusing on the molecular drivers of cancer, targeted therapies can achieve higher efficacy while reducing unnecessary treatments and minimizing side effects. As research progresses, the repertoire of targeted therapies is expected to expand, covering a broader range of cancer types and molecular alterations.[30]

2. Advancements in Precision Oncology:

Precision oncology, an integral part of personalized medicine, revolves around identifying specific alterations driving cancer growth and tailoring treatments accordingly. Precision oncology encompasses not only targeted therapies but also immunotherapies, gene therapies, and other innovative approaches. It aims to optimize patient outcomes by accounting for the individual's tumor biology, genetics, and response to treatment.

Through collaborative efforts among researchers, clinicians, and bioinformatics experts, precision oncology is continuously evolving. New biomarkers and technologies are being developed to better predict treatment response and resistance mechanisms. In the future, precision oncology is expected to revolutionize cancer care by improving treatment efficacy and providing more personalized and effective therapeutic options.[31]

The future of cancer treatment is undoubtedly promising, with personalized medicine and precision oncology at the forefront of advancements. As research and technology continue to progress, the vision of providing each patient with the most effective and tailored treatment plan becomes increasingly attainable, paving the way for improved cancer outcomes and a brighter future in oncology.

Area of Research	Potential Benefits
Immunotherapy	Harnessing the body's own immune system to fight cancer.
Gene therapy	Delivering genes to cancer cells to either kill them or stop them from growing.
Nanomedicine	Using nanoparticles to deliver drugs or other therapies to cancer cells.
Precision medicine	Tailoring cancer treatment to the individual patient's cancer.
Combination therapy	Using two or more therapies together to treat cancer.
Early detection	Finding cancer early, when it is more treatable.
Prevention	Developing ways to prevent cancer from developing in the first place.

X. CONCLUSION

In conclusion, targeted therapies have emerged as a revolutionary approach in cancer treatment, offering new hope for improved patient outcomes. Throughout this discussion, we have explored the significant impact of targeted therapies in various cancer types and the potential they hold for personalized and precise treatment.

Recapitulation of Key Findings:

We have seen that targeted therapies, such as small molecule inhibitors and monoclonal antibodies, have shown remarkable success in cancers like breast cancer, lung cancer, colorectal cancer, melanoma, and leukemias/lymphomas. By specifically targeting key genetic and molecular alterations driving cancer growth, these therapies have demonstrated higher efficacy and reduced toxicities compared to conventional treatments.

Moreover, we discussed the importance of biomarkers in identifying suitable targets for treatment and the integration of targeted therapies into precision medicine. The use of biomarkers and genomic profiling allows oncologists to tailor treatments based on an individual's unique tumor characteristics, leading to more personalized and effective therapies.[32]

POTENTIAL IMPACT OF TARGETED THERAPIES ON CANCER TREATMENT

The potential impact of targeted therapies on cancer treatment is immense. As research advances and more targeted therapies are developed, the landscape of cancer care is expected to undergo a transformative shift. The promise of personalized medicine and precision oncology offers hope for improved survival rates, better quality of life for patients, and a reduced burden of side effects.

By overcoming drug resistance and tumor heterogeneity, targeted therapies may provide long-term control of cancer and increase the likelihood of achieving complete remission in certain cases. Additionally, the integration of targeted therapies with other treatment modalities, such as immunotherapies and combination therapies, has the potential to further enhance treatment outcomes.[32]

In conclusion, targeted therapies have ushered in a new era of cancer treatment, with the potential to transform the way we approach cancer care. The combination of personalized medicine and precision oncology holds great promise in improving patient outcomes and making significant strides in the fight against cancer. As research continues, targeted therapies are expected to play an increasingly central role in the quest for more effective, less toxic, and ultimately curative cancer treatments.[32]

REFERENCES

[1] Yarden, Y., & Pines, G. (2012). The ERBB network: a convergence point of signaling pathways in cancer. Nature Reviews Cancer, 12(8), 623-631.

[2] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.

[3] Garraway, L. A., & Janne, P. A. (2012). Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discovery, 2(3), 214-226.

[4] National Cancer Institute. (2020). Targeted Cancer Therapies. Retrieved from https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet

[5] Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., ... & Kurzrock, R. (2015). Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. Journal of Clinical Oncology, 33(32), 3817-3825.

[6] Drilon, A., & Li, G. (2013). Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncogene, 34(28), 3999-4008.

[7] Oxnard, G. R., Binder, A., & Janne, P. A. (2013). New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology, 31(8), 1097-1104.

[8] Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., ... & Marcom, P. K. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353-360.

[9] Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., ... & Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037.

[10] Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.

[11] Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.

[12] Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., ... & June, C. H. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507-1517.

[13] Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526(7573), 351-360.

[14] . Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell, 161(2), 205-214.

[15] Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.

[16] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., ... & Reckamp, K. L. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New England Journal of Medicine, 373(17), 1627-1639.

[17] Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., ... & Hoeller, C. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375-384.

[18] Chen, D. S., & Mellman, I. (2017). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1-10.

[19] Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.

[20] Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Ladrera, G. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957.

[21] Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., ... & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350(23), 2335-2342.

[22] Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., ... & Huang, B. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. New England Journal of Medicine, 367(2), 107-114.

[23] Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., ... & Fuchs, R. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic

leukaemia: a randomised, open-label, phase 3 trial. The Lancet, 376(9747), 1164-1174.

[24] Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., ... & Boisvert, D. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine, 372(1), 30-39.

[25] Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013). The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine, 9(1), 1-14.

[26] McWilliams, R. R., Kolesar, J. M., & Johnson, C. S. (2012). Promising practices for cancer clinical trials. Cancer Control, 19(3), 184-190.

[27] Mondadori, C., Saccardi, R., & Peccatori, J. (2021). Clinical trials: past, present, and future. The Journal of Bone and Joint Surgery, 103(4), 357-364.

[28] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.

[29] Tannock, I. F., & Hickman, J. A. (2016). Limits to personalized cancer medicine. New England Journal of Medicine, 375(13), 1289-1294.

[30] Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795.

[31] Von Hoff, D. D., Stephenson Jr, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., ... & Sanders Jr, G. (2010). Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. Journal of Clinical Oncology, 28(33), 4877-4883.

[32] Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.